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Abstract
Background: Targeted re-sequencing of candidate genes in individuals at the extremes of a quantitative
phenotype distribution is a method of choice to gain information on the contribution of rare variants to disease
susceptibility. The endocannabinoid system mediates signaling in the brain and peripheral tissues involved in the
regulation of energy balance, is highly active in obese patients, and represents a strong candidate pathway to
examine for genetic association with body mass index (BMI).
Results: We sequenced two intervals (covering 188 kb) encoding the endocannabinoid metabolic enzymes fatty-
acid amide hydrolase (FAAH) and monoglyceride lipase (MGLL) in 147 normal controls and 142 extremely obese
cases. After applying quality filters, we called 1,393 high quality single nucleotide variants, 55% of which are rare,
and 143 indels. Using single marker tests and collapsed marker tests, we identified four intervals associated with
BMI: the FAAH promoter, the MGLL promoter, MGLL intron 2, and MGLL intron 3. Two of these intervals are
composed of rare variants and the majority of the associated variants are located in promoter sequences or in
predicted transcriptional enhancers, suggesting a regulatory role. The set of rare variants in the FAAH promoter
associated with BMI is also associated with increased level of FAAH substrate anandamide, further implicating a
functional role in obesity.
Conclusions: Our study, which is one of the first reports of a sequence-based association study using next-
generation sequencing of candidate genes, provides insights into study design and analysis approaches and
demonstrates the importance of examining regulatory elements rather than exclusively focusing on exon
sequences.
Background
During the past decade, the search for the underlying
genetic basis of complex traits and diseases in humans
has been focused on common DNA variants with a
minor allele frequency (MAF) > 0.05. This approach is
based on the common variant common disease hypoth-
esis [1], our increased knowledge of common variants
[2], and improved genotyping methods [3]. The effort of
the human genetics community has led, through gen-
ome-wide association studies (GWASs), to the identifi-
cation of over 400 genetic loci associated with complex
traits. However, GWASs have uncovered only a small
fraction of the estimated heritability underlying complex
phenotypes. The missing heritability is potentially
accounted for by rare variants or variants in epistasis,
both of which are difficult to identify via current gen-
ome-wide genotyping and analysis strategies. It has been
suggested that sequencing candidate genes relevant to
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quantitative trait will be an efficient means to examine
the contribution of rare variants to the phenotype [4].
Obesity is highly heritable [5] and recent GWASs have
identified variants in approximately 15 genes that are
associated with body mass index (BMI), among which
are FTO [6], MC4R [7] and CTNNBL1 [8]. However,
taken together these genes explain only a small fraction
of the disease heritability [5]. There is little overlap
between the genes identified by GWASs and previous
genes identified through linkage or candidate gene stu-
dies, suggesting that the approaches have different sensi-
tivities, likely due to the fact that GWASs examine only
common variants and require stringent multiple-testing
corrections. The genes associated with obesity risk to
date are involved in several processes, such as adipogen-
esis, energy balance, appetite and satiety regulation.
G e n e si nt h ee n d o c a n n a b i n o i d( E C )s y s t e ma r ek n o w n
to also be involved in regulating physiological functions
associated with obesity [9,10]; the EC receptor 1 gene,
CNR1, has been genetically associated with the trait
[11]. ECs have modulatory effects on energy homeosta-
sis by binding to cannabinoid receptors in the central
nervous system or peripheral tissues, regulating appetite,
food intake or eating behaviors [12,13]. Deregulation of
the EC system has been shown in overweight and eating
disorders, and increased levels of ECs in many tissues is
linked to obesity [14,15].
The fatty-acid amide hydrolase (FAAH)a n dt h e
monoglyceride lipase (MGLL) genes encode enzymes of
the EC system; these catabolize anandamide (AEA) and
2-arachidonyl glycerol (2-AG), respectively. Thus, FAAH
and MGLL enzymatic activity or expression plays a pri-
mary role in regulating metabolite levels of the EC sys-
tem. Circulating levels of AEA and 2-AG are higher in
obese patients and FAAH expression level in adipose tis-
sue is reduced [16,17]. A variant in FAAH (P129T) iden-
tified in obese patients results in reduced FAAH activity
[18,19]. Despite this biological evidence, GWASs have
not found significant association between obesity and
EC system genes. Thus, FAAH and MGLL are excellent
candidates to be sequenced in the extreme of the BMI
distribution to find the extent of their genetic diversity
and potential association of variants with obesity.
Currently, sequence-based association studies need to
target specific intervals in the human genome to allow a
sufficient number of samples to be examined. Several
studies have examined exons to identify rare coding var-
iants implicated in reduced sterol absorption and lower
plasma levels of high-density lipoprotein [20], underlying
cancer initiation and progression [21] and Mendelian
diseases [22]. For complex diseases, regulatory variants
affecting the expression of genes likely play an impor-
tant role, thus justifying the sequencing of larger
intervals, as was done for the 8q24 interval associated
with colorectal cancer [23]. To the best of our knowl-
edge, the approach of deep population sequencing of
large candidate gene intervals has not yet been used for
association studies. This is partly due to the fact that
next-generation sequencing sample preparation and
instruments are not yet optimized to sequence intervals
in a large number of individuals. Additionally, the meth-
ods for using population sequence data to ascertain var-
iant calling, including indels, are still being developed.
Lastly, there is a lack of computational and experimental
methods to analyze rare variants (< 1% allele frequency)
associated with diseases.
In this report, we explore the genetic diversity of
188 kb of sequence encompassing the FAAH and MGLL
genes in 289 individuals and use variants from the
whole allelic frequency spectrum to investigate associa-
tion with extreme obesity (BMI ≥40 kg/m
2). We identify
all the variants present in the two gene intervals, estab-
lish a number of quality filters to generate a set of high
quality variants and perform association testing with
obesity using two different approaches: a chi-square ana-
lysis appropriate for common variants (MAF > 0.01) and
a collapsing method [24] for rare variants (MAF < 0.01).
We identify 20 common variants in MGLL associated
with high BMI and discover three intervals containing
sets of rare variants (referred to as rare locus-variants)
in both MGLL and FAAH. Most of the associated var-
iants lie in regulatory elements, either close to the gene
promoter or in transcriptional enhancers, as determined
by chromatin signatures in HeLa and other cell types. In
addition, we show the association of a rare locus-variant
in the FAAH promoter with increased plasma levels of
AEA, thus providing an independent validation of the
genetic association with obesity.
Results and discussion
Selection of samples at extremes of the BMI distribution
To increase the power of our study to detect variants
associated with extreme obesity in the FAAH and MGLL
genes, we sequenced DNA from individuals at the
extremes of the BMI distribution in the CRESCENDO
cohort, which consists of 2,958 Caucasian individuals
aged 55 years or older and was established to study obe-
sity treatment (average BMI is 35 kg/m
2;F i g u r e1 ) .T h i s
strategy is based on the premise that a significant excess
of sequence variants in one extreme compared to the
other extreme that is not due to stratification is an indi-
cation of genetic association with the phenotype. We
selected 289 individuals of European ancestry from both
tails of the BMI distribution for both genders of the
CRESCENDO cohort; 73 men and 70 women with a
BMI > 40 kg/m
2 (referred to as cases) and 74 men and
72 women with a BMI < 30 kg/m
2 (referred to as
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ple and thus only 24% of our control population has a
BMI < 25 kg/m
2. For this reason, our population is par-
ticularly well suited to identify the genetic variants asso-
ciated with extreme obesity (BMI > 40 kg/m
2).
Targeted sequencing of 188 kb of sequence spanning
FAAH and MGLL
We amplified the 32-kb interval encompassing FAAH
and the 156-kb interval encompassing MGLL by long
range PCR (LR-PCR) using 40 overlapping amplicons
(Figure 2A, B). Of the targeted base pairs, 77% were
covered by two distinct amplicons and the remaining
23% (43.6 kb) located at the edges of the two intervals
were covered by only one amplicon. After equimolar
pooling of the amplicons, each sample was sequenced at
a median coverage greater than 60× across the targeted
intervals (Table S1 in Additional file 1). The median of
the average coverage for the samples was 187×. In all
samples, 85% of the targeted bases were covered at 20×
or more (Figure 2C). To perform sequence-based asso-
ciation studies, the consistency and reproducibility of
coverage across targeted bases from sample to sample is
of high importance. Coverage is directly correlated with
accuracy in base calling and the same bases need to be
analyzed across numerous samples. In general, targeted
sequencing using LR-PCR provides good reproducibility,
ensuring that any particular base will be covered equally
well in different samples, provided there is a sufficient
average coverage depth [25]. However, regions of high
GC content are difficult to amplify and sequence [25]
and in our current study are insufficiently covered in a
number of samples (Figure 2A, B). Restricting the analy-
sis to bases called in greater than 90% of the samples,
we have 99.9% sensitivity to call homozygous bases
(assuming a 3× coverage requirement) and 99.7% sensi-
tivity to call heterozygous bases (assuming a 6× coverage
requirement).
Identification, filtering, and characterization of single
nucleotide variants
We identified 1,448 single nucleotide variants (SNVs)
that are polymorphic in the 289 sequenced samples
using the MAQ SNP calling algorithm [26]. We imple-
mented a number of quality filters to establish a reliable
set of SNVs. We initially examined only the 1,433 SNVs
that were biallelic, of which 1,403 (97.9%) were in
Hardy-Weinberg equilibrium (HWE) at a P-value <
0.001 in the controls. The majority (19 of 27) of SNVs
failing HWE had a lower than expected heterozygosity.
Heterozygous genotypes in sequence data can be under-
called for coverage or quality reasons. We observed a
few cases where a ‘hidden’ variant (SNV or indel) was
located in the vicinity of the SNV that failed the HWE
test, leading to an erroneous call for alignment reasons.
We imposed additional quality criteria where we
assigned an ‘N’ genotype for a SNV covered by less than
three reads or with poor consensus genotype quality
(MAQ phred score < 10). Finally, we removed 16 SNVs
for which less than 90% of the samples had valid geno-
type calls. These successive filters leave us with 1,393
SNVs confidently called in the sequenced cohort (Addi-
tional file 2). In addition to these 1,393 biallelic variants
we also observed 5 tri-allelic variants (Table S2 in Addi-
tional file 1), of which 4 are private variants and
observed only once (MAF = 0.002) and one is observed
three times. This small number of tri-allelic variants
(0.34% of the 1,448 SNVs) is consistent with the propor-
tion of tri-allelic SNPs in the Seattle SNP database,
which contains 67 tri-allelic SNPs (0.224%) [27]. For the
biallelic SNVs identified, 433 of 1,393 (31%) are present
in the dbSNP databases (v.129). Of the 960 (69%) novel
SNVs, 512 (37%) were singletons (the minor allele was
found only once) and 762 (55%) had a MAF < 1%. Since
we sequenced 578 chromosomes, rare variants with a
frequency of approximately 1% will be present in 6
chromosomes, and can thus be reliably identified. Our
results demonstrate the power of deep population re-
sequencing to discover rare variants (Additional file 3).
Coding variants are likely to have large effect sizes and
their functional consequences can be predicted. We
found 14 coding variants, of which 5 are common
(MAF > 0.05) and 9 are rare (MAF < 0.003; observed
only once or twice) (Table 1). Most of the common
variants were previously known whereas the rare var-
iants are novel. Of the 14 coding variants, 4 and 5 are
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Figure 1 BMI distribution in the CRESCENDO cohort (grey) and
in the selected controls (147 samples with BMI ≤ 30 kg/m
2,
blue) and cases (142 samples with BMI ≥40 kg/m
2, red).
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Figure 2 Sequence coverage distribution. (a,b) Genome Browser tracks showing locations of the 40 LR-PCR amplicons (black rectangles), the
number of samples with coverage below 20× (blue histogram, 100-bp windows) and GC percent (red histogram, 10-bp windows) along the
FAAH (a) and MGLL (b) re-sequenced intervals. The ends of the intervals have lower coverage due to the fact they were amplified by a single
amplicon. The 5’ end of the FAAH gene was successfully amplified but coverage is low due to difficulty sequencing high GC content regions.
The high GC content at the 5’ end of the MGLL gene resulted in an inability to successfully design PCR primer pairs despite several attempts. (c)
Distribution of the fraction of bases (y-axis) sequenced at increasing usable coverage (x-axis) for sequence-based association studies. Usable
coverage is defined at each base as the minimum coverage reached by 90% or more of the samples.
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respectively, and 3 of them, all rare, are predicted to be
damaging by SIFT [28]. Interestingly, rs324420, a coding
allele, is predicted as tolerated despite evidence of its
negative effect on FAAH enzymatic activity [19], thus
showing the limitation of the predictive algorithm and
underscoring the value of experimental validation by
functional assays.
Quality assessment of the sequence-based genotypes
The use of next-generation sequencing for association
studies is still an emerging field, and thus base-calling
errors need to be better characterized to avoid con-
founding the association testing analysis. In particular,
one needs to distinguish systematic errors due to the
technology and random sampling errors due to low cov-
erage. Here we use two separate assessment strategies to
estimate the accuracy of our sequencing and define
error types.
Comparison to an alternative genotyping method
To evaluate the accuracy of the filtered genotype calls
using the sequence data, we independently genotyped 19
SNVs, present in dbSNP, in the two sequenced genes
using the MassARRAY genotyping platform. We com-
pared the sequence-derived genotypes for each sample to
the corresponding MassARRAY genotypes and found that
1.8% (97 of 5,487 comparisons) of the genotypes were in
disagreement between the two methods (Table 2). Sixty-
four out of 97 (66%) of the discordant genotypes were
located at three loci. Further inspection of these loci show
that they are systematic errors due to the presence of a
hidden un-annotated variant in the vicinity. The HWE sta-
tistic was higher for the MassARRAY genotypes at two
loci, indicating that the MassARRAY genotyping was
more often incorrect, likely due to the fact that the hidden
variants were not considered during the primer design.
Thirty out of 97 (31%) of the discordant genotypes were
located in 10 of the remaining 13 loci. They were missed
heterozygous in the sequence-based genotypes (N/N) and
were likely a result of low sequence coverage and are thus
random sampling errors. The last three discrepancies were
due to missing genotypes. These results indicate that
sequencing-based genotyping is more robust than Mas-
sARRAY genotyping to the presence of a hidden variant.
A similar genotyping error type has been observed gen-
ome-wide with microarray genotyping, where 85 of 130
discrepant calls were due to ‘hidden’ SNPs [29]. This com-
parison shows us that 1.2% of all genotypes are discordant
due to systematic errors in the genotyping platform
whereas 0.6% are discordant due to low coverage or ran-
dom sampling errors in the sequence data.
Comparison between replicate samples
The above comparison to an established genotyping
method only assesses accuracy at well-behaved bases
Table 1 Coding sequence variants in the two genes and SIFT analysis
Coordinate Alleles Gene Codon
change
a
Amino acid
change
dbSNP Coding type SIFT
prediction
SIFT
score
MAF Number
observed
Chr1_46643348 C/A FAAH CCA-aCA P129T rs324420 Non-
synonymous
Tolerated 0.46 0.216 123
Chr1_46643944 G/A FAAH GGG-aGG G226R Novel Non-
synonymous
Tolerated 0.15 0.002 1
Chr1_46643960 C/T FAAH CCC-CtC P231L Novel Non-
synonymous
Tolerated 0.63 0.002 1
Chr1_46643996 G/A FAAH CGC-CaC R243H Novel Non-
synonymous
Damaging 0 0.003 2
Chr1_46644333 G/A FAAH GAG-GAa E274E Novel Synonymous Tolerated 0.96 0.052 30
Chr1_46644573 T/C FAAH TGT-TGc C299C rs324419 Synonymous Tolerated 1 0.176 101
Chr1_46646834 G/A FAAH GCG-GCa A356A rs45476901 Synonymous Tolerated 1 0.002 1
Chr3_128893754 C/T MGLL GCA-aCA A307T Novel Non-
synonymous
Tolerated 0.55 0.003 2
Chr3_128893854 A/C MGLL ATT-ATg I273M Novel Non-
synonymous
Tolerated 0.13 0.002 1
Chr3_128896571 T/C MGLL CTA-CTg L251L rs4881 Synonymous Tolerated 1 0.073 42
Chr3_128922669 C/T MGLL GCA-aCA A143T Novel Non-
synonymous
Tolerated 0.36 0.002 1
Chr3_128983328 C/T MGLL GAC-aAC D86N Novel Non-
synonymous
Damaging 0 0.002 1
Chr3_129023325 C/T MGLL CGG-CGa R19R rs11538698 Synonymous Tolerated 0.86 0.052 30
Chr3_129023335 G/A MGLL TCC-TtC S16F Novel Non-
synonymous
Damaging 0.01 0.002 1
aChanging nucleotide indicated as lower case.
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well as potential false positive variants, we compared
sequence-based genotypes between independent dupli-
cates of nine samples (independent library preparation
and sequencing runs). We identified 448 SNVs present
in one or more samples of 9 replicated samples; 429 of
these passed the quality control filters established in the
sequenced population, resulting in 1,697 pairs of geno-
types to compare (most SNVs being present in more
than one pair of duplicates). Of these, 1,612 (95%) pairs
matched between the two replicates (Figure 3). Of note,
the 5-kb regions upstream of MGLL and FAAH covered
by single amplicons (Figure 2A, B) had 13 discrepant
pairs; this increased error rate is likely due to the lower
sequence coverage. Fifteen discrepant pairs had low cov-
erage (< 20×) in one sample, which can create random
sampling errors. Five discrepant pairs were homozygous
alternative in one sample and heterozygous in the other.
Table 2 Concordance of the sequence-derived genotype calls with genotypes from the MassARRAY genotyping for 19
SNPs
Hardy-Weinberg statistic
SNP rsID Number matching
genotype
Number of under-
calls
a
Number of over-
calls
b
Number of N/
N
c
Sequencing MassARRAY Hidden
variant
rs594323 253 1 33 2 1.2 4.2 SNP at 22 bp
rs9759081 272 15 2 0 0 8.6 SNP at 19 bp
rs9852837 276 0 13 0 0.2 0.01 Indel at 38 bp
rs4141964 287 1 0 1 1.6 1.2 -
rs324419 287 2 0 0 0.7 0.9 -
rs17203666 289 0 0 0 0.6 0.6 -
rs11715363 286 3 0 0 0.1 0 -
rs17203659 288 1 0 0 0.2 0 -
rs6778770 287 0 1 0 0.2 0.3 -
rs17282181 283 4 2 0 0 0.2 -
rs497897 287 1 1 0 1.2 0.2 -
rs567384 283 4 2 0 2.3 0.6 -
rs3773155 286 3 0 0 0 0 -
rs3773159 286 1 2 0 2.3 2.1 -
rs13076593 288 1 0 0 0.8 0.1 -
rs936839 288 1 0 0 1.1 1.2 -
rs13066225 289 0 0 0 0.1 0.1 -
rs324420 289 0 0 0 0 0 -
rs7652615 289 0 0 0 0.4 0.4 -
aGenotype called as reference homozygote by sequencing and heterozygote by MassARRAY or heterozygote by sequencing and alternative homozygote by
MassARRAY.
bGenotype called as heterozygote by sequencing and reference homozygote by MassARRAY or alternative homozygote by sequencing and
heterozygote by MassARRAY.
cUncalled genotype or tri-allelic in one of the two.
Concordant
Homozygous alternate vs Heterozygous
Homozygous reference vs Heterozygous (near pass error)
Homozygous reference vs Heterozygous (regular error)
Low coverage (<20x)
1612
15 34 31
5
Figure 3 Quality control of SNV identification. Distribution of the matching status of 1,697 genotypes obtained from the 9 replicated
samples.
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ple and homozygous reference in the other, of which 31
h a ds o m ee v i d e n c eo ft h ea l t e r n a t i v ea l l e l ei nt h er a w
consensus call but failed Bayesian SNV caller (referred
to as a near-pass error; see Materials and methods); 34
pairs did not show such evidence for the presence of an
alternative allele. It is important to distinguish near-pass
errors from regular errors s i n c et h e yc a nb er e s c u e d
with optimized SNV calling or leveraging population
information [30]. Our analysis reveals that in 289 sam-
ples, only 2.8% ((15 + 34)/1,697) of all variants were
likely miscalled due to random sampling, whereas 2.1%
((31 + 5)/1,697) show an alternative allele under-calling,
which was not sufficient to create Hardy-Weinberg dise-
quilibrium. These data demonstrate that targeted
sequencing using LR-PCR as the sample preparation
method produces high sample-to-sample variant calling
reproducibility.
Detection of indels
The identification of insertions and deletions from short
reads (36 bp) remains a challenge for two reasons: it is
computationally prohibitive to align millions of short
reads to a reference sequence allowing for gaps; and the
alignments with indels are not reliable for short reads.
The availability of paired-end reads alleviates the first
problem since one end of the read can be anchored on
the reference sequence and the second end can then be
gap-aligned using a full Smith-Waterman alignment.
According to previous reports, the SNV:indel ratio var-
ies from 10:1 to 7:1 [29,31]; thus, we expect to find
approximately 140 indels in the re-sequenced region.
We used the MAQ indelpe module to perform paired-
end mapping of the reads and to identify potential indel
positions in each sample. This method identifies a large
number of false positives and requires additional filter-
ing to reliably call indels in the population. We identi-
fied 240 potential indel positions, 54 of which match an
entry and allele call in dbSNP (v.129). Of the 240 indels,
106 are single base pair indels, 53 of them are located in
homopolymer runs of 5 bp or longer and 24 in runs of
10 bp or longer, 21 indels are 2 bases long and, of these,
14 are located di-nucleotide repeats of length 2 or more;
143 indels pass HWE testing in the control samples, of
which 49 match an allele in dbSNP. Interestingly, 5
indels failing HWE testing are bona fide variants present
in dbSNP. The percentage of indels passing the HWE
test (59.6%) is considerably lower than that of SNVs
(97.9%), reflecting the difficulty to accurately call indels
using short-read technology.
By sequencing 142 high BMI cases and 147 low BMI
controls, we overall identified 1,393 high-confidence
SNVs and 143 indels passing HWE testing for use in
sequence-based association studies.
Association of variants with BMI
As the sequenced samples were selected from the two
tails of the BMI distribution, we performed association
tests for each SNV with BMI as a binary trait to deter-
mine if any of the identified sequence variants in the
FAAH and MGLL genes are associated with high BMI.
We performed sequence-based association analysis using
two different approaches: a chi-square analysis on all
variants and a collapsing method for lower frequency
variants.
Single marker tests
We compared the allele frequencies of the variants in
the cases and controls and assessed statistical signifi-
cance using allelic chi-square test for each variant. Nine-
teen SNVs and one indel show an association with BMI
(Table 3; chi-square P-value ≤ 0.01), of which 16 remain
associated (P < 0.01) and 4 marginally associated (P-
value approximately 0.01) after performing 5,000 permu-
tation tests (Table 3). These associated variants are
located in the non-coding part of the MGLL gene: three
variants upstream, seven in intron 2 and ten in intron 3
(Figure 4A). The 20 associated variants are split between
two linkage disequilibrium (LD) blocks demarcated by a
recombination hotspot (Figure 4A) and could potentially
affect regulatory elements located upstream or intronic
to the gene. The variants in the left block have a lower
frequency (MAF < 0.05) than the ones in the right block
(MAF > 0.15). Interestingly, the risk effects of the minor
alleles in the left and right blocks are opposite; most of
the minor alleles in the right block are protective while
most of those in the left block are associated with risk
(Table 3). Of note, four of the associated variants were
present on at least one of the genotyping arrays used in
the original obesity GWASs (Table 3) but were not
found associated with the trait. It is important to note
that our study design, which is looking at extreme obe-
sity (BMI ≥40 kg/m
2)i na no v e r w e i g h tp o p u l a t i o n
(mean BMI = 35 kg/m
2), is different from most pub-
lished GWASs, which missed the association at the
MGLL loci.
Several other SNPs located in FTO [6,32-35], MC4R
[7,36,37], CNR1 [11,38,39], CTNNBL1 [8], INSIG2 [40]
or PFKP [35] have been associated with high BMI or
obesity by GWASs. In order to relate these previous
results to the population in our study, we genotyped the
associated SNPs in the 289 individuals we sequenced.
Looking at BMI as a binary trait, we found that all the
SNPs located in FTO were associated with high BMI (P-
value < 0.05; Table S3 in Additional file 1). None of
SNPs located in the other genes showed association
with high BMI. These results demonstrate that despite
differences in the sample selection criteria, our cohort is
appropriate to replicate the association of variants in the
FTO gene interval, one of the strongest associations in
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meta-analysis of the majority of published obesity
GWASs, the authors show that the replication of the
INSIG2 locus association was compromised by study
design [41]. Thus, the failure to replicate originally
weaker associations in our study and the failure to iden-
tify MGLL in previous GWASs can be due to insuffi-
cient power, population differences, variable study
designs or selection criterion.
Collapsed marker tests with RareCover
Statistical association with single variants of low allele
frequency is challenging to assess as very few samples
contribute to the association test. Previous studies have
used collapsing methods to study the influence of rare
variants on high-density lipoprotein plasma levels [42],
colorectal cancer risk [43] or type 1 diabetes [44]. More
recent collapsing methods use a weighted or multivari-
ate model. Here, we implement a model-free method
(RareCover [24]; see Materials and methods) to identify
an optimal set of variants of low allele frequency (MAF
≤ 0.1) within a moving 5-kb window, which maximizes
the association with high BMI. We refer to variants in
the 5-kb window as locus-variants. This strategy
increases the power of detecting an association using
variants of low allele frequency with moderate relative
risk and cohort sizes.
Using RareCover on the low frequency SNVs (MAF <
0.1, indels excluded), we identified 31 locus-variants in
the FAAH and MGLL interval that are significantly asso-
ciated (permutation P-value < 0.01; Table S4 in Addi-
tional file 1) with extreme obesity (Figure 4B, C). Most
of these locus-variants are overlapping and share several
SNVs; however, three distinct intervals show significant
association with high BMI. The first interval is located
in the FAAH promoter region. The most significant
locus-variant of this interval harbors 15 variants selected
by RareCover for maximizing the association (permuta-
tion P-value = 2.2 × 10
-3; Table S4 in Additional file 1).
Twenty-three cases and no controls carry a minor allele
at the union of the 15 variants (Table S5 in Additional
file 1). The second interval is located in the MGLL pro-
moter region. RareCover identified 10 variants (permu-
tation P- v a l u e=1 . 4×1 0
-3) in the most significant
locus-variant of this interval; 38 cases and 9 controls
carry a minor allele at the union of the 10 variants
(Tables S4 and S5 in Additional file 1). Thus, for both
genes, the most significantly associated locus-variants
are located upstream of the transcription start sites with
potential consequences on the regulation of gene
expression. Because these upstream regions have lower
coverage due to their amplification by a single amplicon
(Figure 2A, B), we verified that all SNV alleles found
Table 3 List of variants associated with high BMI by single marker tests
MAF Chi-square Permutation
LD block SNV-ID Chr 3 coordinate Gene location Minor/major alleles Cohort Cases Controls P-value OR P-value
Left rs16830415 128956957 Intron3 C/T 0.028 0.045 0.010 9.95E-03 4.59 8.00E-03
Chr3_128957192 128957192 Intron3 G/T 0.028 0.045 0.010 9.95E-03 4.59 8.00E-03
Chr3_128958587 128958587 Intron3 C/T 0.043 0.066 0.021 6.70E-03 3.39 5.00E-03
Chr3_128958866 128958866 Intron3 -/T 0.08 0.049 0.1103 7.07E-03 0.41 7.40E-03
rs9832418 128961356 Intron3 C/T 0.028 0.045 0.010 9.95E-03 4.59 8.00E-03
rs547801
a 128964929 Intron3 T/C 0.029 0.049 0.010 5.93E-03 4.96 5.00E-03
rs520154
a 128965687 Intron3 A/G 0.028 0.049 0.007 2.04E-03 7.46 1.20E-03
rs60963555 128967982 Intron3 T/C 0.026 0.045 0.007 3.52E-03 6.91 1.60E-03
rs684358
b 128969940 Intron3 G/T 0.028 0.049 0.007 2.04E-03 7.46 1.20E-03
rs9852837 128973744 Intron3 A/G 0.028 0.045 0.010 9.95E-03 4.59 1.16E-02
Right rs9289319 129009856 Intron2 G/A 0.192 0.138 0.243 1.42E-03 0.50 1.80E-03
rs9289320 129010946 Intron2 G/C 0.192 0.143 0.240 3.27E-03 0.53 6.00E-03
rs9289321 129011459 Intron2 A/G 0.165 0.123 0.206 7.84E-03 0.54 9.80E-03
rs9877819
c 129012220 Intron2 A/G 0.164 0.122 0.206 7.03E-03 0.54 7.40E-03
rs28753886 129013477 Intron2 A/G 0.163 0.119 0.206 4.79E-03 0.52 5.60E-03
rs35948688 129014938 Intron2 C/T 0.159 0.112 0.206 2.10E-03 0.49 2.40E-03
rs874546
c 129021102 Intron2 G/A 0.183 0.140 0.226 8.99E-03 0.56 1.00E-02
rs2011138 129026619 Upstream A/C 0.352 0.412 0.295 3.18E-03 1.68 4.40E-03
Chr3_129026621 129026621 Upstream A/G 0.049 0.021 0.075 2.65E-03 0.27 4.00E-03
Chr3_129029015 129029015 Upstream A/G 0.336 0.398 0.276 1.98E-03 1.74 3.60E-03
aPresent on the Affymetrix 500 k genotyping array.
bAlso part of a locus-variant associated with high BMI using the collapsed marker test RareCover (Table S5 in
Additional file 1).
cPresent on the Illumina HumanHap300 genotyping array. LD, linkage disequilibrium.
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RareCover collapsing method, has sufficient coverage
(Table S8 in Additional file 1) to generate reliable geno-
types. Finally, the third interval is located in MGLL
intron 3 and overlaps with the left block SNVs asso-
ciated with high BMI by singlem a r k e ra n a l y s i s( F i g u r e
4A, B). It has only one significant locus-variant (P-value
= 0.0096) consisting of 9 variants; 25 cases and 2
controls carry a minor allele of the union of the 9 var-
iants (Table S5 in Additional file 1). One of the nine
variants in the MGLL intron 3 locus-variant (rs684358)
was also identified as associated with high BMI in the
single marker analysis. Interestingly, the eight other var-
iants associated with BMI using single marker analysis
are not included in the reported significant locus-
variants. This is due to the fact that these variants are in
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Figure 4 Association with BMI. (a) Significance of the association with BMI identified by single marker tests (-log10(chi-square P-value)) for all
SNVs located in the MGLL interval (x-axis, NCBI36 coordinates). SNPs with a P-value < 0.01 are highlighted in red. The recombination rate [56] in
the HapMap CEU population for this region is indicated by a blue line and measured on the right axis. (b,c) Significance of the association with
BMI for all locus-variants identified by RareCover (see Materials and methods) in the MGLL (a) and FAAH (b) sequenced intervals. For both genes,
locus-variants with a P-value < 0.01 are highlighted in red. The MGLL and FAAH gene structures are aligned based on their genomic positions.
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same individual: their addition in the RareCover locus-
v a r i a n tw o u l dn o tc h a n g et h eP-value and thus they
were not included. Although these eight variants are
included in some other locus-variants, the P-value does
not reach significance since its calculation differs from
the single marker test by the inclusion of other variants
and the finite number of permutations. The second
most associated variant by the single marker test
(rs520154) is included in a mildly significant locus-var-
iant (P-value approximately 0.03); the seven other var-
iants had a higher single-marker P-value. Of note, the
right block identified by the single marker analysis har-
bors only more common variants (MAF > 0.15), which
were not included in the RareCover analysis. Thus, in
the same interval of MGLL intron 3, both the single
marker and RareCover tests independently identified
variants with different MAFs (approximately 0.03 versus
approximately 0.002) that are associated with high BMI.
Functional annotation of the associated variants
DNA variants located outside of coding regions can lie
in transcriptional regulatory elements and have an effect
on gene expression. In order to determine the potential
regulatory function of the variants or locus-variants
associated with high BMI, we inspected publicly avail-
able chromatin marks around the MGLL and FAAH
genes. In particular, the combined location on the DNA
sequence of several histone modifications as well as
transcriptional co-activators and RNA polymerase has
been used in HeLa cells to determine genome-wide sig-
natures for transcriptional enhancers and promoters
[45]. Interestingly, the MGLL interval has 11 predicted
enhancers in HeLa cells; however, there are no predicted
enhancers in the FAAH interval (Figure 5, track B). The
locus-variant identified by RareCover in MGLL intron 3
and also identified via single marker test (Figure 5, track
A) overlaps an enhancer prediction. Chromatin marks
corresponding to this particular enhancer are also iden-
tified in several cell types studied by the ENCODE con-
sortium [46] (Figure 5, track C). In addition, a number
of transcription factors bind this particular element in
HeLa cells as shown by the ENCODE consortium [46]
(Figure 5, track D) adding further evidence that it is
likely to be an enhancer. Since enhancers can be active
in multiple cell types, it is very likely that the variants
associated with high BMI in MGLL intron 3 affect the
activity of a transcriptional enhancer by modifying a
transcription factor binding site, thus changing MGLL
gene expression in the central nervous system or other,
peripheral tissues. Similarly, one of the single associated
SNVs in MGLL intron 2 also lies in an enhancer predic-
tion. This particular SNV could well be associated with
high BMI because of its causal regulatory role in MGLL
expression while the other SNVs in the right block
could be associated because of their LD with it. Interest-
ingly, none of the associated variants are present in evo-
lutionarily conserved sequences, which frequently are a
signature for regulatory elements. These analyses sug-
gest that two of the intervals (MGLL intron 2 and intron
3) associated with high BMI contain regulatory variants
in enhancer elements.
Consequences of associated variants on EC levels
Reduced levels of FAAH and MGLL catabolic enzymes
can lead to an accumulation of their substrates AEA
and 2-AG, respectively. In an attempt to link the pre-
sence of the associated alleles in high BMI patients to
the level of circulating EC, we measured the plasma
concentrations of AEA and 2-AG in a subset of the
samples. We selected 96 obese patients with BMI > 45
kg/m
2 and 48 normal patients with BMI < 26 kg/m
2
and measured the concentration of AEA and 2-AG in
the plasma using reverse phase liquid chromatography
coupled to triple-quadrupole mass spectrometry
(TQMS). We calibrated our measurements by compari-
son to deuterated standards.
None of the single variants located in MGLL and asso-
ciated with high BMI showed a significant association
with either AEA or 2-AG levels. Examining the most
significantly associated locus-variants from each of the
three intervals identified by RareCover, we compared
AEA and 2-AG average levels between carriers in the
obese samples versus non-carrier control samples (Table
4). Case individuals carrying the locus-variant minor
alleles in FAAH had significantly higher levels of AEA
(+24%) than control non-carrier individuals (t-test P-
value = 0.05), with a consistent trend across all classes
(carrier/cases, non-carrier/cases, non-carriers/controls)
(Figure S2 in Additional file 4). This trend is consistent
with the higher observed levels of AEA in obesity [16],
which could result from reduced expression of FAAH in
some obese individuals because of rare variants in the
promoter region (Table 4).
Conclusions
In this study, we generated high quality sequencing data
to analyze the association of DNA variants in two candi-
date genes, FAAH and MGLL, with extreme obesity.
Deep population sequencing allows one to test for the
association of alleles spanning the entire frequency spec-
trum. By using two different approaches, single marker
tests and collapsed marker tests, we were able to identify
one interval in the FAAH promoter and three intervals
in the MGLL gene, one each in the promoter, intron 2,
and intron 3, all associated with high BMI. Most of the
associated variants are rare (MAF < 0.01) or have low
frequencies (MAF ≈ 0 . 0 3 )a n da r eo n l ya c c e s s i b l ev i a
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obtained in the sequencing-based association study
allowed us to precisely map the associated variants to a
predicted transcriptional enhancer in HeLa cells or to
the promoter regions. Thus, the associated variants are
likely regulating the expression of MGLL and FAAH.B y
potentially affecting the overall transcription rate of the
two genes, the variants can influence the EC degradation
rate. A correlation between decreased expression of
FAAH in adipose tissues and increased circulating AEA
levels has previously been observed in obese patients
[16]. The expression of FAAH and MGLL in numerous
tissues will make it challenging to determine the exact
role that the regulatory variants identified in our study
play in obesity.
Our study design examines extreme cases of obesity in
an overweight population. We demonstrate the ability to
replicate in our population the association of FTO var-
iants with obesity, which is the main BMI-associated
locus, thus further proving the robustness of the associa-
tion and the appropriate selection of our samples to
study obesity. However, some other loci, more weakly or
inconsistently associated in the original GWASs, were
not replicated in our samples, which is not too surprising
given the sample size of our cohort is inadequate to repli-
cate modest associations. Reciprocally, the published
GWASs did not find any association in FAAH or MGLL
despite the presence of probes for 4 out of 20 single mar-
ker-associated variants in the genotyping microarrays
used. This lack of consistency has been studied through a
meta-analysis of obesity GWASs [41] in which replication
was compromised by the type of population sampled, the
BMI thresholds used for cases and controls, the fraction
of obese people, or the time of study reflecting change in
the environment. This study highlights the crucial impor-
tance of population and study design in obesity associa-
tion studies for both discovery and replication. It is
important to note that, in our study, we strengthen the
initial genetic association by correlating it to its func-
tional consequences in both FAAH and MGLL.U s i n g
metabolite measurements in the plasma of the sequenced
s a m p l e s ,w ev e r i f i e dt h a tt h es e to fr a r ev a r i a n t si nt h e
FAAH promoter associated with high BMI is also asso-
ciated with an increased level of AEA. Additionally, we
demonstrate independent associations of common and
rare variants in MGLL intron 3 and show that these var-
iants overlap a predicted transcriptional enhancer, which
suggests their regulatory role.
The large number of loci identified by GWASs only
explains a small fraction of the estimated heritability
underlying complex diseases. Since GWASs using arrays
examine only common variants for association, it is
Scale
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Figure 5 Functional annotation of the associated variants in the MGLL interval. Track A: variants identified by the single marker tests (blue
bars) or the merge of the locus-variants identified by the collapsed marker test RareCover (red boxes) are indicated. Track B: predicted intervals
for promoters (green) or transcriptional enhancers (orange) in HeLa cells [45]. Tracks C and D: the distribution of chromatin binding proteins
from the ENCODE data obtained from the UCSC genome browser (15 November 2009). Track C: Broad/MGH ENCODE group chromatin
signatures corresponding to enhancers (H3K4me1, H3K27ac) and promoters (H3K4me1+3, Pol2) in various cell types (GM12878, HUVEC, K562,
Keratinocytes) [46]. Track D: Yale/UCD/Harvard ENCODE group identified AP2a and g, c-Myc, Max, c-Fos and Pol2 binding sites in HeLa cells, and
STAT1 binding sites in HeLa treated with IFNg [46].
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ponent of the hidden heritability. Compared with pre-
vious GWASs, sequencing-based studies can examine
rare variants for association with complex traits. It is
believed that a significant fraction of the heritability
missed by GWASs lies in rare variants. Similar to our
approach, other studies have collapsed rare variants
from several samples to assess a significance difference
in frequency between two groups [42,44]. Although the
effect size of rare variants cannot be accurately esti-
mated in a relatively small cohort, it has been shown
that they contribute to an incremental fraction of herit-
ability in hypertrigyceridemia [47]. Our study is the first
to use this approach on contiguous genomic intervals
and not only in coding regions. This allows the identifi-
cation of potential regulatory variants. Most common
variants found in GWASs of common diseases lie in
non-coding regions, often very distant from genes.
These variants, or variants in LD with them, are thought
to affect regulatory elements, as some studies have
demonstrated [48,49]. The effect of the rare variants in
common diseases might be similar and more frequently
affecting regulatory elements: this hypothesis fits parti-
cularly late-onset or chronic disease etiology in which
the symptoms can be the result of long-term mild
imbalance in the regulation of molecular functions. As
sequencing technology and bioinformatics tools
improve, we will be able to reliably call copy-number
variation in large cohorts and consider gene interactions
to explore even further the missing heritability.
In order to improve the sensitivity of genetic associa-
tion studies, the biology underlying the complex pheno-
type also needs to be considered. For this purpose, the
epigenetic landscape, such as chromatin marks, is parti-
cularly important to identify the functional variant from
a group of associated variants all in LD and go beyond
the pure genetic assessment of disease susceptibility.
Knowledge of the biochemical activity of the gene pro-
ducts is also helpful. For example, the extensive annota-
tion of metabolic pathways constitutes a powerful
paradigm with a direct measurable output. We
sequenced two genes coding for metabolic enzymes
important for the regulation of the EC system, and
looked upstream of their consequences on BMI, at the
level of their substrates, to confirm their influence.
Thus, an integrated approach using deep sequencing to
find rare variants, epigenetic annotation of the DNA
sequence and functionally relevant endo-phenotypes
Table 4 Average endocannabinoid levels of FAAH and MGLL rare variant carrier groups at the most significant locus-
variants in the three intervals
AEA 2-AG
N Average (pmol/ml) SD P-value
a N Average (pmol/ml) SD P-value
a
FAAH promoter locus-variant 0.05 0.10
Carrier
Cases 14 17.11 5.79 14 10.55 10.67
Controls 0 NA NA 0 NA NA
Non-carrier
Cases 80 15.13 5.34 67 5.63 3.04
Controls 48 13.76 5.51 35 6.98 4.15
MGLL intron 3 locus-variant 0.49 0.80
Carrier
Cases 5 15.6 6.35 4 6.43 2.08
Controls 0 NA NA 0 NA NA
Non-carrier
Cases 89 15.24 5.44 77 6.49 5.57
Controls 48 13.76 5.52 35 6.99 4.16
MGLL promoter locus-variant 0.36 0.37
Carrier
Cases 26 15.09 5.6 24 6.31 3.06
Controls 3 13.16 5.38 3 4.41 4.46
Non-carrier
Cases 68 15.56 5.43 57 6.56 6.2
Controls 45 13.8 5.58 32 7.22 4.11
aTwo-tailed t-test P-value between carriers/cases and non-carriers/controls. NA, not available.
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ability and helps to more fully comprehend the under-
pinnings of complex disease etiology. With increasing
availability of large scale functional datasets, integrated
approaches such as ours will likely become more com-
mon in future genetic association studies.
Materials and methods
Selection of samples for sequencing
The Institutional Review Board of Sanofi Aventis
approved the collection of samples from the CRES-
CENDO cohort [50] and the unrestricted release of the
results of this study. The enrollment of participants and
blood collection were carried out in accordance with the
Helsinki Declaration. In particular, patients gave
informed consent to the study. An initial list of 3,101
individuals in the CRESCENDO cohort were evaluated
and filtered to select low and high BMI/obesity samples,
representing the two extremes of this phenotype, for
both genders. Individuals of European ancestry are
highly represented (96%) in the CRESCENDO cohort.
To reduce false-positive findings due to differing genetic
backgrounds, male and female selection was restricted
to individuals of European ancestry, ranging in age from
55 to 77 years. Samples with inconsistent or aberrant
measurements were removed from the set, including 52
samples from patients with inconsistent waist measure-
ments (standard deviation > 3), 2 samples with missing
biographical data, and from one subject with a nonsensi-
cal BMI (BMI = 195). For the low BMI/obesity sample
subset, male and female subjects with a BMI of ≤ 30 kg/
m
2 were selected. For the high BMI/obesity sample sub-
set, male and female subjects with a BMI of ≥40 kg/m
2,
but < 60 kg/m
2, were selected to remove aberrant out-
liers. The last criterion used for selection was the waist
measurement. First, the BMI measurements were
plotted against the average waist measurements, and
two outliers on the BMI/waist measurement graph were
removed. Based on availability and quality of DNA, a
subset of each category was selected for deep population
sequencing: 73 men and 70 women with a BMI > 40
kg/m
2 and 74 men and 72 women with a BMI < 30 kg/
m
2 (Figure 1). DNA was isolated from whole blood col-
lected from each of the 289 selected individuals.
Differences in ancestry between cases and controls can
lead to spurious associations in case-control association
studies. Although all individuals in the CRESCENDO
cohort that were selected for sequencing have self-
reported European ancestry, we utilized a set of ancestry
informative markers to ensure that the sequenced sam-
ples have primarily European ancestry; 31 ancestry
informative markers chosen from the Human Diversity
Panel [51] were genotyped in the 289 samples using the
Sequenom MassARRAY genotyping platform. We
performed principal components analysis of the geno-
type data [52] using Matlab (MathWorks, Natick, MA,
USA) and only the first principal component was signifi-
cant, indicating lack of population structure.
Long-range PCR
Forty LR-PCR experiments were performed to amplify
31,716 bp encompassing the FAAH gene (NCBI36
chr1:46621328-46653043) and 156,556 bp encompassing
the MGLL gene (NCBI36 chr3:128880456-129037011).
We performed the 40 LR-PCR experiments using 5 ng
of genomic DNA, 0.5 μM forward LR-PCR primers, 0.5
μM reverse LR-PCR primers (Table S6 in Additional file
1) in a total reaction volume of 12 μl, as described [2].
Following LR-PCR, the 40 amplicons (3,129 bp to
12,203 bp) generated using a single DNA sample tem-
plate were quantified using Quant-IT technology (Invi-
trogen, Carlsbad, CA, USA) and combined in equimolar
amounts using a liquid handling robot (Biomek NX;
Beckman Coulter, Brea CA, USA).
Illumina GAI library preparation
The following steps were performed in 96-well microti-
ter plates unless otherwise specified. The pooled ampli-
cons (1 μg) were fragmented to an average size of 200
bp (between 170 and 250 bp) using 0.005 U of DNase I
for 15 minutes at 37°C followed by an inactivation step
of 10 minutes at 99°C. The fragmented DNA was puri-
fied in a Qiaquick 96 PCR purification plate (QIAGEN,
Valencia, CA, USA) following the manufacturer’s
instructions. The DNA ends were repaired in a 100 μl
reaction (1× NEB ligase buffer, 1 mg/ml bovine serum
albumin, 200 μM dNTP) using 15 U T4 DNA polymer-
ase (NEB Ipswich, MA, USA), 50 U T4 polynucleotide
kinase (NEB), and 5 U Klenow DNA polymerase. The
reaction was incubated for 30 minutes at 20°C and the
DNA purified on a Qiaquick 96 PCR purification plate.
The 3’ end was extended with a single overhanging A
using 15 U Klenow exo-, 200 μMd A T Pi n5 0μlN E B 2
reaction buffer and incubated for 30 minutes at 37°C.
The DNA was purified on a Qiaquick 96 PCR purifica-
tion plate. The eluted DNA was mixed with 10 μMo f
indexed adapters (see sample indexing below and Table
S6 in Additional file 1) and ligated for 15 minutes at
room temperature with 2,000 U DNA ligase in 50 μl
ligase buffer (NEB) followed by purification on a Qia-
quick 96 PCR purification plate. The DNA was sepa-
rated from the free adapters by 2% agarose gel
electrophoresis, the smear ranging from 120 to 210 bp
was extracted, melted in 3 μl QG buffer per milligram
of gel for 20 minutes at 50° in a 800 μl deep well micro-
titerplate and purified using a Qiaquick 96 PCR purifica-
tion plate. The adapter ligated fragments were then
enriched by PCR using the library enrichment primer
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taining 4 μl template DNA, Phusion HF buffer (NEB),
200 μMd N T P ,0 . 4μMo fb o t hS o l e x ap r i m e r s ,3 %
DMSO, 0.5 μl Phusion DNA polymerase. The PCR
involved denaturing for 5 minutes at 98°C followed by
20 cycles of 10 s at 98°C; 20 s at 65°C, 15 s at 72°C, and
a final elongation of 4 minutes at 72°C. The DNA
library was then purified on a Qiaquick 96 PCR purifica-
tion plate.
Sample indexing and sequencing
In order to sequence several samples per lane on the
Illumina GA flow cell, we implemented an indexing
strategy similar to that described in Craig et al.[ 5 3 ] .
We generated 12 pairs of modified DNA adaptors with
4 nucleotide DNA barcodes at the 3’ ends; the first and
last nucleotides of the DNA barcode were constant
while the two middle nucleotides vary (CNNT; Table S6
in Additional file 1). Both strands of the indexed adapter
(Integrated DNA Technologies Coralville IA, USA) were
mixed at 100 μM in TE pH 8.0, denatured for 5 minutes
at 95°C, placed in a heat block at 70°C, left at room
temperature until reaching 25°C, and then transferred to
4°C and left overnight, enabling the two strands to
anneal. The annealed strands were then stored at -20°C.
The libraries were quantified by Quant-IT technology
(Invitrogen) in quadruplicate, diluted to 10 nM. From
one to seven indexed libraries were combined together
into one pool, denatured with NaOH, and then 2.3 pM
of each pool was loaded into one lane of an Ilumina GA
flow cell and sequenced using Illumina Single-Read
Cluster Generation Kit v1 and SBS Kit v1 for 40 cycles,
thus providing 36-nucleotide reads after removal of the
4 nucleotides used for DNA barcoding. All the sequen-
cing data are publically available from NCBI short read
archive study #SRP003433.
Image analysis pipeline, read alignment and variant
calling
We used the Illumina Pipeline version 1.0 to analyze the
raw images, masking the first four bases of the index
(USE_BASE option IIIIY*) for accurate base call calibra-
tion. After base calling, quality calibration and read fil-
tering, Python scripts were used to parse out the
indexes and create the sequence files for each sample.
For paired-end reads, we used the index of the high
quality first read to assign the read to a particular sam-
ple, regardless of the index from the lower quality sec-
ond read (matching in > 95% of the cases).
We used MAQ (version 0.6.8) [26] to align the reads
to the reference sequence allowing for three mismatches
in the first 24 bp (maq map -n 3). The 289 sample
libraries were sequenced across multiple runs of the
Illumina GA, 250 samples were sequenced with only
paired-end runs, 38 samples were sequenced with at
least one paired-end run, and one sample was
sequenced in single reads only. For samples sequenced
multiple times (with the exception of technical replicate
samples of the MultiQC set; see below), the mapped
reads were merged to create a single set of mappings for
each sample (maq mapmerge). The MAQ variant calling
method was used to call variants using default para-
meters (maq.pl SNPfilter was used to filter out false
positives) for each sample. MAQ assigns a most likely
genotype for each site and detects potential SNVs in
each individual. The set of variants across all 289 sam-
ples was combined to create the list of 1,451 raw var-
iants. For each SNV site, we used the MAQ cnsview
files to determine the genotype for each sample and the
coverage and consensus quality at every position. Geno-
types with a quality score below 10 or covered by less
than three reads were assigned the NN genotype.
Detection of insertions/deletions
MAQ outputs all read alignments with indels. We used
the filtered indelpe files as the initial set of potential
indels. We used the following steps to determine a reli-
a b l es e to fi n d e l sf r o mt h eindelpe files. Step 1, we
merged the set of indels reported by MAQ for all 287
samples (2 samples did not have enough paired-end
reads). Step 2, we clustered together the indels in multi-
ple samples based on the position of the indels in the
reference sequence. This is required since indels located
in homopolymer stretches of sequence can have multi-
ple starting locations. Step 3, for each individual, we
assigned the genotype for an indel as heterozygote if the
proportion of the non-reference reads was between 0.2
and 0.8. Step 4, the genotype was assigned as reference
homozygote and alternative homozygote if the propor-
tion was less than 0.2 and more than 0.8, respectively.
Step 5, for each indel detected in the population, we
required at least one sample to have three reads with
the indel variant and at least eight reads covering the
variant site. We imposed stringent cutoffs for rare indels
(MAF < 0.01). For such indels, we required coverage of
at least 10 with 5 reads containing the indel variant.
Genotyping HapMap SNPs
The SNPs were genotyped using the Sequenom MassAr-
ray genotyping platform. We selected 19 HapMap CEU
tag SNPs from the two gene regions (3 in FAAH and 16
in MGGL; Table S7 in Additional file 1). PCR assays
and extension primers for t h e s eS N P sw e r ed e s i g n e d
using the MassARRAY Assay Design software, version
3.1 (Sequenom San Diego CA, USA). SNPs were geno-
typed using the iPLEX Gold assay, based on multiplex
PCR followed by a single base primer extension reac-
tion. The mass of the primer extension products,
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assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry. Final genotypes were
called using the MassArray Type, version 4.0.
Genotyping obesity SNPs
The genotypes were determined after PCR and 5’ nucle-
ase assay (allelic discrimination with ABI TaqMan speci-
fic probes) reaction and read on an ABI 9700 (LIFE
Technologies, Carlsbad, CA USA) The PCR primers and
probes were chosen according to the supplier (LIFE
Technologies, Carlsbad, CA USA). All reagents and soft-
ware used are licensed to Applied Biosystems. The gen-
otypes were analyzed on an ABI7900 automated
sequencer and determined using the SDS2.0(r) allelic
discrimination software. No deviations from Hardy-
Weinberg proportions were detected; the genotyping
failure rate was 1%.
Sample sets for quality control
The nine samples were processed as blind replicates,
meaning each replicate was treated as an entirely sepa-
rate sample with independent PCR amplification, library
preparation and sequencing as well as analysis. The
resulting genotype pairs were compared, assigning the
following matching status: 1, concordant between repli-
cates; 2, heterozygous versus homozygous alternative; 3,
heterozygous versus homozygous reference with evi-
dence of alternative allele in the raw data (second most
likely genotype - near-pass error); 4, heterozygous versus
homozygous reference without evidence of alternative
allele; 5, low covered position (< 20×) in one of the
replicates resulting in erroneous genotypes.
Single marker association
The test for association was performed using PLINK1.06
[54]. The SNPs were filtered for HWE in the controls
and genotyping rate > 0.9. We performed a binary case/
control association using a chi-squared test (–assoc),
considering high BMI samples as cases and low BMI
samples as controls. The max(T) permutation P-value
(–mperm 5000) was obtained after performing 5,000
sample label permutations.
Association with rare variants
We used the RareCover algorithm described in Bhatia et
al. [24]. Briefly, we define S as the set of rare variants
(MAF ≤ 0.1) present at a locus LS, which is a window of
size 5 kb. RareCover examines overlapping windows,
where each window is shifted one rare variant away
from the previous rare variant. We define C as a subset
of S composed of rare variants that contribute to AC,
the union-variant, a virtual construct that combines the
effects of multiple rare variants. The variants in C
together form a locus-variant LC,a n df o ra ni n d i v i d u a l
sample AC = 1 if at least one of the variants carries the
minor allele, and otherwise AC =0 .B yu s i n gac h i -
square statistic test between high and low BMI samples
at the locus LC, we find the optimal subset of rare var-
iants C for which the association is maximal, thus defin-
ing the test-statistic for the locus LS.T h el e v e lo f
significance was obtained by performing 10
4 randomiza-
tions of the data set, permuting cases and controls, and
re-computing the test-statistic for the selected locus-var-
iant with the permuted samples. A locus LS is consid-
ered significant if the permuted P-value is < 0.01. To
correct for the total number of locus-variant windows
tested per gene, another 10
6 permutations of cases and
controls were performed and used to evaluate the signif-
icance of all locus-variants in the gene [24]. The three
locus-variants reported in our study all had a P-value ≤
0.05 when corrected for the number of windows tested.
Evolutionarily conserved sequences
Conserved bases were defined as nucleotides with a con-
servation score ≥0.1758 (5th percentile in the interval)
in the multispecies sequence comparison track at UCSC
(28 way placental mammals PhyloP conservation score).
Measurement of endocannabinoid levels in plasma
Whole blood samples were collected in evacuated glass
tubes containing EDTA. Samples were centrifuged to
separate plasma from blood cells and plasma was with-
drawn and stored in 1-ml aliquots at -80°C prior to
plasma lipid extraction. For each sample, 0.5 ml plasma
was added to a glass vial containing 2.0 ml chloroform
(CHCl3) ,1 . 0m lm e t h a n o l( M e O H )a n d0 . 5m l( 1 %v / v )
formic acid. To this mixture were added aliquots of 10
pmol D5-2-arachidonlyglycerol (2-AG) and 5 pmol D8-
arachidonlyethanolamine (AEA). Vial contents were vor-
tex mixed for 30 s and centrifuged at 10°C (1400 × g for
10 minutes). The organic layer was carefully removed
avoiding the aqueous layer and dried under a stream of
nitrogen (N2) gas. The lipid layer was then re-solubilized
in 100 μl of 2:1 CHCl3:CH3OH.
Quantitative analysis of EC metabolites using the
deuterated standards for AEA and 2-AG together with
calculation of the other EC metabolites was based on a
ratio to the deuterated standards and was performed on
an Agilent 6410 liquid chromatography triple-quadru-
pole mass spectrometer using positive ion analysis
mode. For each sample, 20 μl of re-solubilized plasma
lipids were injected into the TQMS and EC metabolites
were measured by multiple reaction monitoring using
the following transitions: 348 > 62 (AEA), fragmentation
energy = 8; and 379 > 287 (2-AG), fragmentation energy
= 11. Chromatography was performed using the follow-
ing solvents: A, 95:5:0.1 H2O:methanol:formic acid; and
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Page 15 of 18B, 60:35:5:0.1 isopropanol:methanol:H2O:formic acid.
Lipids were injected into a 5 micron particle size C18
column (50 × 4.6 mm) from Phenomenex (Torrance,
CA, USA) and eluted with a 10-minute solvent B gradi-
ent from 60% to 100%. Values for each EC metabolite
were subsequently calculated using ratios to the deuter-
ated internal standards to calculate absolute concentra-
tions, expressed as picomoles (pmol) of EC metabolite
per milliliter of plasma similar to current methods [55].
Additional material
Additional file 1: Supplementary tables.
Additional file 2: Supplementary Figure S3. Flowchart illustrating the
filtering steps for the variant calling.
Additional file 3: Supplementary Figure S1. Distribution of the minor
allele frequencies in the sequenced population for SNVs present in
dbSNP (light grey) or novel SNVs (dark grey) in the FAAH and MGLL
sequenced intervals.
Additional file 4: Supplementary Figure S2. Average AEA plasma
levels (pmol/ml) in 48 non-carriers controls, 80 non-carrier cases and 14
case carriers of the most significant FAAH variant-locus allele associated
with high BMI. Error bars represent the standard deviation from the
mean.
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